cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara
Biotech
Summary
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For China, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketChina
- ImpactMedium (56/100)
- SignalFunding